EN DE
Watch Xcell Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Xcell Therapeutics Inc (373110) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Xcell Therapeutics Inc stock KRW 680, price KRW 808, that is 15.8% below the price, quality 22 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

XT Xcell Therapeutics Inc logo Thin data Nov 10, 2026

Xcell Therapeutics Inc

373110 · KQ
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Expensive Growth (revenue 3y +24.1 %/yr in KRW)
Mixed vs. peers (4/9)
Fair value 680.21 KRW · Overvalued
Quality 22/100
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Xcell Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

8,269 KRW 779.00 KRW Fair Value 680.21 KRW Jul 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

28‑month range 779.00 KRW – 8,269 KRW · fair‑value band 510.16 KRW – 850.26 KRW · the 808.00 KRW price screens above the 680.21 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Xcell Therapeutics in your weekly email

Every Wednesday you see whether Xcell Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells.

Show moreShow less

The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors.

Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.

Stock analysis

Xcell Therapeutics Inc (373110) currently trades at 808.00 KRW, while our estimate is 680.21 KRW, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 510.16 KRW (bear) to 850.26 KRW (bull), the price of 808.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Xcell Therapeutics Inc reported revenue of 1.9B KRW in FY2025 versus 2.0B KRW in FY2021, a compound −0.2%/yr. Reported net income was −10.9B KRW in FY2025.

Key figures

Market cap 16.9B KRW (≈ $12.7M) Micro · P/S ratio 3.88 · EPS (TTM) −657.18 KRW · Return on equity −271% · Return on assets (EBIT) −57.3% (5-year average) · Operating margin −142% · Revenue (TTM) 4.4B KRW · Revenue growth (YoY) +775%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, 373110 screens richer than that median.

Fair Value

Bear 510.16 KRW Fair Value 680.21 KRW Bull 850.26 KRW
Price 808.00 KRW · Downside -15.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 66
Does it invest with discipline instead of growing at any price?
Low Volatility 18
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 17
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−290.1% (2021) → −556.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

373110 screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Xcell Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −15.8% · Above median
Profitability
Return on assets −69.5% · Bottom 25%
Operating margin (12 months) −142.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 775.4% · Top 25%
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.37× · Cheaper than median
P/S (12 months) 3.88× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 373110
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 373110
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 373110
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 373110
argenx SE ARGX $971.55 $908.40 −7% vs 373110
CSL Limited CSL A$201.68 A$181.40 −10% vs 373110
Moderna, Inc MRNA $250.83 $158.70 −37% vs 373110
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 373110
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 373110
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 373110

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xcell Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Xcell Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/373110

Frequently asked questions

Is Xcell Therapeutics Inc (373110) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 680.21 KRW versus a price of 808.00 KRW, about 16% lower (overvalued).
What is the fair value of 373110?
Our estimate for Xcell Therapeutics Inc is 680.21 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 808.00 KRW.
What is the quality score of 373110?
Xcell Therapeutics Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xcell Therapeutics Inc (373110)?
Our calculated price target is the estimate of 680.21 KRW (as of Nov 10, 2026). Cautious scenario 510.16 KRW, optimistic scenario 850.26 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Xcell Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at 680.21 KRW, about 16% lower versus a price of 808.00 KRW (overvalued). Cautious scenario 510.16 KRW, optimistic scenario 850.26 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Xcell Therapeutics Inc (373110)?
Xcell Therapeutics Inc reported trailing-twelve-month revenue of about 4.4B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Xcell Therapeutics Inc (373110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xcell Therapeutics Inc it is 680.21 KRW per share (as of Nov 10, 2026), against a price of 808.00 KRW.
Is Xcell Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 373110 trades above its calculated fair value: price 808.00 KRW, fair value 680.21 KRW, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 373110?
No. The price is what the market pays today (808.00 KRW); the fair value is what the company's own numbers justify (680.21 KRW). For Xcell Therapeutics Inc the two are 127.79 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Xcell Therapeutics Inc worth?
The market values Xcell Therapeutics Inc at about 16.9B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 808.00 KRW; our models calculate a fair value of 680.21 KRW per share.
What do the bullish and bearish scenarios say about 373110?
Our models span a range for Xcell Therapeutics Inc: cautious scenario 510.16 KRW, base 680.21 KRW, optimistic 850.26 KRW per share (as of Nov 10, 2026, price 808.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xcell Therapeutics Inc (373110)?
Balance-sheet figures for Xcell Therapeutics Inc (as of Nov 10, 2026): return on equity −271.4%, debt of 0.14 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is 373110 from its 52-week high?
Xcell Therapeutics Inc trades at 808.00 KRW, about 63% below its 52-week high of 2,170 KRW and 4% above the low of 779.00 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 680.21 KRW is for.
Which stocks are comparable to Xcell Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xcell Therapeutics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 808.00 KRW, calculated fair value 680.21 KRW (−16%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Xcell Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xcell Therapeutics Inc (373110)?
The closing price on Nov 10, 2026 was 808.00 KRW. Our estimate is 680.21 KRW, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xcell Therapeutics Inc right now?
Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Xcell Therapeutics Inc

How large is the market capitalisation of Xcell Therapeutics Inc (373110)?
The market capitalisation of Xcell Therapeutics Inc is 16.9B KRW (≈ $12.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xcell Therapeutics Inc (373110)?
The price-to-sales ratio of Xcell Therapeutics Inc is 3.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xcell Therapeutics Inc (373110)?
Earnings per share at Xcell Therapeutics Inc are −657.18 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xcell Therapeutics Inc (373110)?
The return on equity (ROE) of Xcell Therapeutics Inc is −271% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xcell Therapeutics Inc (373110)?
On an EBIT basis the return on assets of Xcell Therapeutics Inc is −57.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xcell Therapeutics Inc (373110)?
The operating margin of Xcell Therapeutics Inc is −142% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xcell Therapeutics Inc (373110)?
Revenue at Xcell Therapeutics Inc is growing +775% versus a year earlier (3y avg +24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Xcell Therapeutics Inc (373110) generate?
The free cash flow of Xcell Therapeutics Inc is −10.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Xcell Therapeutics Inc (373110) carry?
The net debt of Xcell Therapeutics Inc is 2.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Xcell Therapeutics Inc in the live analysis

One click puts Xcell Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.